← 返回前沿论文

通过 SATB1 调控增强嵌合抗原受体-T 细胞抗肝肿瘤疗效

英文原题:Enhanced anti-liver tumor efficacy of chimeric antigen receptor-T cells via SATB1 modulation.

PubMed 2025/12/10(内容时间) Cell Death Dis Q1 · IF 12.2(JCR 2025)

研究概要

我们的研究揭示了SATB1作为一个多功能调节因子,同时靶向耗竭和记忆分化,为增强CAR-T对抗实体瘤的疗效提供了一种新策略。

中文摘要

尽管嵌合抗原受体(CAR)T细胞疗法在治疗血液系统恶性肿瘤方面取得了显著成功,但其在实体瘤中的临床应用受到免疫抑制性肿瘤微环境(TME)中持续性T细胞耗竭的严重阻碍。在此,我们鉴定出SATB1——一个调控染色质架构的基因组组织者——是CAR-T细胞耗竭的关键抑制因子。在靶向Glypican-3(GPC3)的CAR-T细胞中,SATB1在肿瘤浸润性耗竭细胞群中显著下调。SATB1过表达不仅降低了多种抑制性受体(PD-1、CTLA-4、TIM3和LAG-3)的表达,还促进了中央记忆表型,增强了体外对肝细胞癌(HCC)细胞的细胞因子产生和细胞毒性。在体内,SATB1工程化CAR-T细胞表现出更优的肿瘤控制能力并促进生存,同时肿瘤浸润性T细胞中的耗竭标志物减少。这些功能改善与SATB1在调节T细胞耗竭中的已知作用一致,使其成为CAR-T细胞适应性的多功能增强因子。总之,我们的研究揭示了SATB1作为一个多功能调节因子,同时靶向耗竭和记忆分化,为增强CAR-T对实体瘤的疗效提供了一种新策略。

展开英文摘要原文

Although Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable success in treating hematopoietic malignancies, its clinical application in solid tumors is profoundly hindered by persistent T-cell exhaustion within the immunosuppressive tumor microenvironment (TME). Here, we identified SATB1-a genome organizer regulating chromatin architecture-as a key suppressor of CAR-T cell exhaustion. In Glypican-3 (GPC3)-targeted CAR-T cells, SATB1 was significantly downregulated in tumor-infiltrating exhausted populations. SATB1 overexpression not only reduced expression of multiple inhibitory receptors (PD-1, CTLA-4, TIM3, and LAG-3) but also promoted a central memory phenotype, enhancing cytokine production and cytotoxicity against hepatocellular carcinoma (HCC) cells in vitro. In vivo, SATB1-engineered CAR-T cells exhibited superior tumor control and promoted survival, accompanied by reduced exhaustion markers in tumor-infiltrating T cells. These functional improvements are consistent with the reported role of SATB1 in modulating T cell exhaustion, positioning it as a multifunctional enhancer of CAR-T cell fitness. Collectively, our study unveils SATB1 as a multifunctional modulator that simultaneously targets exhaustion and memory differentiation, offering a novel strategy to enhance CAR-T efficacy against solid tumors.

论文信息

作者
Zhang L、Cheng C、Bi X、Cao J、Li X、Zhao T
第一作者单位
State Key Laboratory of Organ Regeneration and Reconstruction, Institute for Stem Cell and Regeneration, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.China
通讯作者单位
State Key Laboratory of Organ Regeneration and Reconstruction, Institute for Stem Cell and Regeneration, Institute of Zoology, Chinese Academy of Sciences, Beijing, China. tbzhao@ioz.ac.cn.China
期刊
Cell death & disease2025 Dec 10
原文标识
PubMed 41372119 · DOI 10.1038/s41419-025-08307-3